A recent longitudinal study from the University of Toronto reveals the mental health consequences of the COVID-19 pandemic on older adults living with migraine.
Drugmakers seize on biomarkers to test the FDA’s rare disease shift
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS